Company Description
Shockwave Medical, Inc., a medical device company, develops and commercializes intravascular lithotripsy (IVL) technology for the treatment of calcified plaque in patients with peripheral and coronary vascular, and heart valve diseases in the United States and internationally.
The company offers products for the treatment of peripheral artery disease (PAD), including M5 IVL catheter and M5+ IVL catheter, which are five-emitter catheters used in IVL system in medium-diameter vessels; S4 IVL catheter, a four-emitter catheter for use in IVL system in small-diameter vessels; and L6 IVL catheter, a six-emitter catheter used for IVL System in large diameter vessels.
It also provides product for the treatment of coronary artery disease, such as C2 IVL catheter and C2+IVL catheter that are two-emitter catheters for use in IVL system; and Reducer, a device to treat refractory angina.
In addition, the company develops COSIRA-II trial; shockwave C2 Aero, a coronary IVL catheter; shockwave javelin coronary, a non-balloon-based catheter platform to treat of tight, difficult-to-cross coronary lesions; shockwave L6; shockwave E8 catheter, to target long peripheral artery lesions; shockwave javelin peripheral, a non-balloon-based catheter platform, to treat tight, difficult-to-cross peripheral lesions.
Further, it offers shockwave carotid IVL, a purpose-built IVL System to treat calcified carotid artery lesions; and Shockwave Crescendo, a platform developed to treat calcified, stenotic heart valves.
It serves interventional cardiologists, vascular surgeons, and interventional radiologists through sales representatives and managers, and distributors.
The company was incorporated in 2009 and is headquartered in Santa Clara, California. As of May 31, 2024, Shockwave Medical, Inc. operates as a subsidiary of Johnson & Johnson.
| Country | United States |
| IPO Date | Mar 7, 2019 |
| Industry | Medical Devices |
| Sector | Healthcare |
| Employees | 1,468 |
| CEO | Douglas E. Godshall M.B.A. |
Contact Details
Address: 5403 Betsy Ross Drive Santa Clara, California 95054 United States | |
| Phone | (510) 279-4262 |
| Website | shockwavemedical.com |
Stock Details
| Ticker Symbol | SWAV |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $17.00 |
| CIK Code | 0001642545 |
| CUSIP Number | 82489T104 |
| ISIN Number | US82489T1043 |
| Employer ID | 27-0494101 |
| SIC Code | 3841 |
Key Executives
| Name | Position |
|---|---|
| Douglas E. Godshall M.B.A. | President, Chief Executive Officer and Director |
| Isaac Zacharias | Chief Commercial Officer |
| Daniel Hawkins | Founder and Senior Advisor |
| John M. Adams | Co-Founder and Technical Advisor |
| Renee M. Gaeta | Chief Financial Officer |
| Luis Morales | Senior Vice President of Global Operations |
| Trinh Phung | Chief Accounting Officer, Principal Accounting Officer and Vice President of Finance |
| Debbie Kaster | Vice President of Investor Relations |
| Hajime Tada J.D. | General Counsel and Secretary |
| Robert Fletcher | Senior Vice President of Marketing and Market Access |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| May 31, 2024 | S-8 POS | Securities to be offered to employees in employee benefit plans, post-effective amendments |
| May 31, 2024 | S-8 POS | Securities to be offered to employees in employee benefit plans, post-effective amendments |
| May 31, 2024 | S-8 POS | Securities to be offered to employees in employee benefit plans, post-effective amendments |
| May 31, 2024 | S-8 POS | Securities to be offered to employees in employee benefit plans, post-effective amendments |
| May 31, 2024 | S-8 POS | Securities to be offered to employees in employee benefit plans, post-effective amendments |
| May 31, 2024 | S-8 POS | Securities to be offered to employees in employee benefit plans, post-effective amendments |
| May 31, 2024 | POSASR | Filing |
| May 31, 2024 | 8-K | Current Report |
| May 31, 2024 | 25-NSE | Filing |
| May 30, 2024 | 8-K | Current Report |